Elron Electronic Industries has reached an agreement with the Israeli government over the sale of its subsidiary, Elbit Medical Imaging of Haifa, according to a March 22 company statement. The government’s approval had been in question since the
Elron Electronic Industries has reached an agreement with the Israeli government over the sale of its subsidiary, Elbit Medical Imaging of Haifa, according to a March 22 company statement. The governments approval had been in question since the beginning of the month, when Israels Office of the Chief Scientist hinted that it wouldnt support the sale until it had finished an investigation, and that Elron might be required to reimburse the government for past R&D loans (SCAN 3/31/99).
After meeting with officials from the Office of the Chief Scientist and executives from Europe IsraelElbits buyer Elron announced that the parties have reached a complete understanding. The conflict between Elron and the Israeli government seemed to be resolved in part by assurances that Elron, Europe Israel, and Elbit will continue to support Israeli high-tech concerns.
Tel Aviv-based Europe Israel and Elbit plan to invest a total of $45 million in Israeli high-tech industries, including $10 million to $20 million for image-guided therapy R&D. Haifa-based Elron emphasized thatwith last Decembers sale of Elscints MRI, nuclear medicine, and CT businesses to General Electric and Picker International (SCAN 12/16/98), as well as the sale of ElbitEurope Israel, GE and Picker will contribute approximately $150 million to Israeli high-tech industries, a third of which will come from the two U.S. firms.
In other news, Elscint last month announced its fourth quarter and fiscal 1998 results (end-December). The company posted net income for the fourth quarter of $29.9 million. Revenues for the period were $35.8 million, compared with $80.4 million in 1997. Operating loss for the quarter was $20.3 million, which Elscint attributed to its low sales from October to November. Net income for the year was $28.2 million, up from 1997s $709,000, while consolidated revenues were $262.1 million, compared with $303 million the year before.
New CT and MRI Research Shows Link Between LR-M Lesions and Rapid Progression of Early-Stage HCC
January 2nd 2025Seventy percent of LR-M hepatocellular carcinoma (HCC) cases were associated with rapid growth in comparison to 12.5 percent of LR-4 HCCs and 28.5 percent of LR-4 HCCs, according to a new study.
Study Examines Impact of Deep Learning on Fast MRI Protocols for Knee Pain
December 17th 2024Ten-minute and five-minute knee MRI exams with compressed sequences facilitated by deep learning offered nearly equivalent sensitivity and specificity as an 18-minute conventional MRI knee exam, according to research presented recently at the RSNA conference.